Abstract: The concept of Integrated Approaches to Testing and Assessment (IATA) has been advanced by the Organisation for Economic Cooperation and Development (OECD) member countries to enable a progressive shift from traditional chemical assessments largely based on the observation of the adverse effect in animal models, using individual methods or predefined batteries of standard toxicity tests, to assessment strategies integrating diverse lines of evidence. The flexible nature of IATA allows the inclusion of mechanistic data generated with non-animal methods and with new technologies (e.g. high-throughput and high content methods). The assessment process within IATA is typically conducted through weight-of-evidence which inevitably includes the elements of subjective expert judgement. For these reasons, IATA cannot be fully harmonized across sectors and countries. Nevertheless, some of the IATA components, such as defined approaches, which consist of a fixed data interpretation procedure (DIP) applied to data generated with a defined set of information sources, can be harmonized. The focus of this MiniReview is to provide an illustration of the differences between the IATA developed so far in the areas of regulatory toxicology, and ongoing activities related to the international harmonization of defined approaches that rely on multiple non-animal information sources.
Integrated Approaches to Testing and Assessment (IATA) are considered science-based approaches for toxicological decision-making, based on the integration of multiple information sources such as physicochemical properties, non-testing methods (e.g. quantitative structure-activity relationship models, grouping and read-across) and testing methods (e.g. in vitro, in vivo), that can be designed and applied for a variety of regulatory purposes [1, 2] . The IATA generic structure consists of a sequential approach that can be summarised in three steps/ parts: (i) the collection of existing information relevant for the chemical under evaluation; (ii) the weight-of-evidence evaluation of the gathered information that may enable regulatory decision-making regarding potential hazard and/or risk or may indicate what additional information is needed for a sound assessment; and (iii) the generation of new testing data to support the conclusion ( fig. 1 ). In those toxicological areas where non-animal methods are available (e.g. skin corrosion/irritation, eye damage/irritation, skin sensitisation), the transition from traditional toxicology to more focused and hypothesisdriven approaches making use of all available relevant information, including non-animal data, is already taking place and harmonization of these approaches has been attempted through documentation by the OECD in different guidance documents.
IATA for Skin Irritation and Corrosion and for Serious Eye Damage and Eye Irritation
Skin corrosion/irritation is an area of regulatory toxicology where a substantial number of in vitro methods have been validated and adopted by the OECD, that is Test Guidelines 1 430, 431, 435 and 439 [3] [4] [5] [6] . This progress enabled the establishment of an IATA for identifying the hazard potential of chemicals for skin corrosion and irritation [7] . In the context of this IATA, if the collected information (part 1) is not sufficient to conclude and new testing is required (part 3), a combination of skin corrosion and skin irritation in vitro tests should be used in first place. In vivo testing should be performed only as a last resort for example in those cases where in vitro methods are not suitable for testing the specific substance or if the results of the in vitro tests are not adequate for the regulatory need. This IATA provides a harmonized framework that can be used across regions and jurisdictions and guarantees in the vast majority of cases the acceptance of in vitro data for the purpose of classification and labelling according to the United Nations Globally Harmonised System of Classification and Labelling of Chemicals (UN GHS). The OECD Guidelines for the testing of chemicals are internationally agreed testing methods used by governments, industry and independent laboratories to assess the safety of chemical products.
Another example of IATA that has recently been developed is the one for serious eye damage and eye irritation [8] . Also in this case, a number of in vitro methods are available and provide the means for generating new data under part 3 of the IATA. In vitro methods described in Test Guidelines 437, 438, 460 and 491 [9] [10] [11] [12] can be used for identifying chemicals causing serious eye damage (GHS Category 1), whereas in vitro methods described in Test Guidelines 437, 438 [9, 10] , 491 and 492 [12, 13] are able to identify chemicals not requiring classification. Classification of GHS Category 2 chemicals (eye irritation) can be concluded only with a weight-of-evidence approach. Thus, the decision process within the IATA for serious eye damage and eye irritation IATA cannot be fully standardised at the moment and for this reason, there is no assurance for international use and acceptance of in vitro data in cases where conclusions are derived on the basis of weight-of-evidence.
IATA for Skin Sensitisation
The skin sensitisation area has been constantly evolving over the last decade thanks to the development, validation and regulatory adoption of non-animal methods that measure essential chemical and biological mechanisms at the basis of the acquisition of skin sensitisation [14] [15] [16] [17] . OECD TG 442C, 442D and 442E [18] [19] [20] describe in chemico or in vitro methods to measure reactivity towards model peptides, to detect keratinocyte inflammatory responses and to quantify the expression of markers of dendritic and monocytic cell activation, respectively. The OECD non-animal tests, when used in isolation, do not provide the same level of information as the regulatory in vivo tests (e.g. LLNA) [21] , and in addition, they are considered insufficient to cover the complexity of the biological mechanisms occurring in vivo. The results obtained with these methods are proposed in the respective Test Guidelines to be used in conjunction with other relevant information in the context of IATA. IATA for skin sensitisation may be constructed depending on the regulatory purpose. In addition, the body of evidence that may be used within the IATA depends on the regulatory requirements. Most likely, for hazard identification purposes information needed for the assessment may be less than the evidence required for more complex regulatory needs (e.g. risk assessment). It is therefore envisaged that in the area of skin sensitisation, different IATA solutions may be possible depending on the chemical under investigation, the regulatory need and the specific regulatory requirements in the different regions [22] . A generic IATA for skin sensitisation is the one proposed in the European Chemicals Agency's (ECHA) guidance to industry on Information Requirements and Chemical Safety Assessment (Chapter R 7.a, section R.7.3 Skin sensitisation) [23] . The ECHA guidance, revised to comply with the changes made to the REACH legal text adopted in 2016 making the use of in vitro methods for skin sensitisation testing a standard information requirement and the primary choice over in vivo studies [24] , describes the scope and limitations of the adopted alternative methods to help registrants using them to fulfil the information requirements under REACH. In addition, it proposes an IATA, called in the document 'testing and assessment strategy' for skin sensitisation assessment which also illustrates how information on the first three key mechanisms of the induction of skin sensitisation generated with the validated non-animal alternative methods can be considered in a weight-of-evidence approach. Although the guidance recommends the testing and assessment strategy to be followed, it acknowledges that other approaches may be more appropriate depending on the specific case.
IATA and Defined Approaches
Due to their flexible nature, IATA cannot be fully prescribed; nevertheless, some of the IATA components such as 'defined approaches' are expected to be standardised. This is because defined approaches are based on a fixed set of information sources and a fixed data interpretation procedure (DIP) to convert inputs from the different information sources into a prediction ( fig. 2 ). The concept of defined approaches was recently developed at the OECD to clarify the difference with IATA, including the fact that defined approaches are proposed to be generally used as elements within IATA [1] .
In the area of skin sensitisation, a variety of defined approaches have been developed integrating data generated with computational, in chemico, in vitro methods and combined with other relevant information such as physicochemical properties. These defined approaches not only vary in relation to the set of information sources used but also differ in the data interpretation procedures applied for converting the input data into a final prediction. However, the data interpretation procedures have a common denominator that they are rulebased and do not require expert knowledge to derive a prediction. Defined approaches may be devised as sequential testing strategies involving interim decision steps at the end of each tier or by applying specific mathematical and statistical models to convert the inputs generated with the different information sources into a prediction.
Defined approaches for skin sensitisation have generally been developed to incorporate the use of mechanistic data from the OECD adopted methods together with other relevant information to predict responses in the LLNA. In addition, their potential to predict human responses has also been explored [e.g. [25] [26] [27] [28] . Some of these approaches have comparable performance to the LLNA for the identification of skin sensitisation hazard; others have been devised to provide potency information [29] .
With a view to support the evaluation of IATA in regulatory decision-making within OECD Member Countries, the OECD has developed and published Guidance Document No. 255 that provides a set of principles and templates for harmonizing the reporting of defined approaches that can be used as one of the components within IATA [1] . As a proof of their workability, the templates have been used to document twelve case studies on defined approaches developed for skin sensitisation and reported in Annex 1 to OECD Guidance Document 256 [30] .
This OECD Guidance Document [30] does not endorse any specific defined approach provided in the case studies, but rather illustrates of how individual information sources and defined approaches developed for skin sensitisation assessment should be reported in a harmonized way.
Nevertheless, harmonized reporting is not sufficient to guarantee effective deployment and acceptance of predictions generated with defined approaches by regulatory authorities. To define additional actions to further promote application and regulatory consideration of defined approaches, in October 2016, the European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) organized in collaboration with the International Cooperation on Alternative Test Methods (ICATM), an international workshop on the regulatory applicability and acceptance of non-animal approaches to skin sensitisation, which was hosted by the European Commission's Joint Research Centre. The workshop brought together representatives from more than 20 regulatory authorities from the EU, USA, Canada, Japan, S. Korea, Brazil and China with the intent to discuss and promote additional activities to facilitate standardisation and acceptance of defined approaches for skin sensitisation.
One of the workshop aims was mapping the regulatory requirements for skin sensitisation across jurisdiction and sectors. It was recognised that differences in regulatory requirements exist, but chances to satisfy such requirements with the use of non-animal methods and defined approaches were also emphasised [31] . The workshop participants also indicated that international harmonization and standardisation are essential to guarantee regulatory uptake of data generated with defined Fig. 2 . Generic example of defined approach and its role within IATA. The figure also shows that, if fit-for-purpose, the prediction generated with the defined approach may directly answer the specific regulatory need. approaches and their use within IATA and recommended the development of an evaluation framework that would allow an independent and consistent evaluation of the defined approaches documented in Annex I to OECD Guidance Document 256 [30] and any other upcoming promising defined approaches. In addition, participants proposed relevant assessment criteria such as biological plausibility, inclusion of existing validated in vitro methods covering key biological mechanisms, accessible data interpretation procedures and performance using reference chemicals to be main elements of the assessment framework. The need to evaluate the variability of the in vivo reference data (animal and human) for the assessment of defined approaches was also discussed. From the discussions, it became evident that the certainty required by end-users and regulatory authorities to facilitate deployment and acceptance of defined approaches may only be guaranteed if they attain the same regulatory status as the standard in vivo method(s) [32] .
Based on these premises, the EU, USA and Canada with the support of the other ICATM partners committed to propose to the OECD a project for the development of international standards for defined approaches. The process leading to the development of such standards foresees the development of an evaluation framework as suggested by the workshop participants and the consistent and independent evaluation of defined approaches for skin sensitisation using this framework. Defined approaches that meet the criteria of this framework and are scientifically valid and fit-for-purpose should be covered by an OECD instrument (e.g. a Test Guideline) that would fall under the regime of Mutual Acceptance of Data (MAD) within OECD-associated countries. The Mutual Acceptance of Data [33] requires test data generated in any OECD member country in accordance with OECD Test Guidelines and OECD Principles of Good Laboratory Practice shall be accepted in other member countries for purposes of assessment and other uses relating to the protection of man and the environment. This reduces duplicative testing, allows governments to work together when assessing chemicals, and saves government and industry resources.
The project was accepted by the Working Group of the National Coordinators for the Test Guidelines Programme (WNT) and is currently underway. A dedicated meeting of the WNT to specifically discuss aspects related to the implementation of this project and agree on the main criteria to be included in the evaluation framework was hosted by the Joint Research Centre of the European Commission in December 2017. The co-leaders of the project are now working on the assessment of the defined approaches against the agreed criteria.
Conclusions
Integrated Approaches to Testing and Assessment are flexible solutions to testing and assessment and for some toxicological end-points they have been described in OECD guidance documents. The weight-of-evidence nature of the assessment process within IATA makes it difficult to fully harmonize such approaches especially for the more complex end-points where integration of data obtained with various types of information sources is needed. The fixed nature of defined approaches should however provide standardisation in the way information obtained with non-animal methods is combined to generate outputs comparable to standard in vivo Test Guidelines. Efforts have been made globally to promote standardised reporting of defined approaches to facilitate their application and evaluation by assessors. Moreover, discussions have started at the OECD to develop instruments to guarantee deployment of defined approaches and acceptance of the predictions by regulatory authorities in the different regions so that defined approaches have the same level of global acceptance as the standard in vivo method(s). The area of skin sensitisation is currently driving these discussions, which may be relevant to the more complex regulatory end-points in the future.
